ReviewJournal of biomedicine & biotechnology2011
Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.
Review in Journal of biomedicine & biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.Clinical drug investigation · 2020Trial
- Review
- Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.Clinical rheumatology · 2023Review
- Accumulation of Senescent Neural Cells in Murine Lupus With Depression-Like Behavior.Frontiers in immunology · 2021Article
- Interferon Genes Are Influenced by 17β-Estradiol in SLE.Frontiers in immunology · 2021Article
- UMP-CMP kinase 2 gene expression in macrophages is dependent on the IRF3-IFNAR signaling axis.PloS one · 2021Article
- Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors.International journal of molecular sciences · 2020Article
- Neuropsychiatric lupus: new mechanistic insights and future treatment directions.Nature reviews. Rheumatology · 2019Review
- The Possible Effect of B-Cell Epitopes of Epstein-Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus.Frontiers in immunology · 2018Article
- Strong viral associations with SLE among Filipinos.Lupus science & medicine · 2017Article
- Article
- Primary and secondary central nervous system vasculitis: clinical manifestations, laboratory findings, neuroimaging, and treatment analysis.Clinical rheumatology · 2015Article
- Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.Therapeutic advances in musculoskeletal disease · 2013Article
- Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.Viruses · 2012Review
- MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha.Cellular & molecular immunology · 2012Article
- Recurrent aseptic meningitis in association with Kikuchi-Fujimoto disease: case report and literature review.BMC neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-specific autoantibodies particularly against ribonucleoproteins. In the current paper, our aim is to summarize the latest findings supporting the association of type I IFN pathway with specific clinical manifestations in the setting of SLE providing insights on the potential use of type I IFN as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.